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. Introduction
here is an increasing national focus on measuring, reporting,
d rewarding the provider’s quality of care based on objective
easures of performance (1). The conceptual and methodolog-
al issues underlying the development of individual perfor-
ance measures have previously been described (2), yet little
s been written about the methods used to combine multiple
dividual metrics into summary or “composite” performance
easures. The goals of this document are to 1) explore the uses
, and challenges associated with, composite performance
easures in assessing healthcare quality; 2) discuss methods
ed in their creation; and 3) set forth some general principles for
propriate development, validation, application, and interpreta-
n of composite measures.
. Definition of Composite
erformance Measures
composite performance measure is the combination of 2 or
ore indicators into a single number to summarize multiple
mensions of provider performance and to facilitate compar-
ons. Composite measures are used in many areas, including
sessment of intelligence such as intelligence quotient,
oduct ratings (Consumer Reports), and stock market valu-
ion (e.g., the Dow-Jones Industrial Average). The present
cument focuses specifically on the use of composite mea-
res in healthcare provider performance assessment. These
easures encapsulate relatively broad concepts, such as the
erall quality of care, or may have a more focused perspec-
e, such as adherence to a specific set of treatment guide-
es. Examples include US News & World Report Annual
dex of Hospital Quality (3), the Centers for Medicaid and inedicare Services Hospital Quality Incentive Demonstration
mposite quality score (4), and the Society of Thoracic
rgeons (STS) coronary artery bypass graft surgery com-
site performance measure (5).
In the present document, the term provider is used gener-
ally to refer to any of the various levels of the healthcare
stem whose performance may be evaluated, such as an
dividual practitioner, practice group, hospital, or healthcare
an. The term developer denotes the individual or group that
velops the composite performance measure. The term user
presents the intended consumers of this information, such
providers, payers, government regulators, or the public.
he terms measure, metric, and indicator are used inter-
angeably in this document.
. Rationale for Creating
omposite Performance Measures
omposite performance measures have a variety of uses.
me important functions are:
ata reduction. A large and growing array of individual
indicators makes it possible for users to become over-
loaded with data. A composite measure reduces the
information burden by distilling the available indicators
into a simple summary.
ope expansion. The information in a composite measure is
highly condensed, making it feasible to track a broader
range of metrics than would be possible otherwise. Com-
posite measures have been described as a tool for making
provider assessments more comprehensive (1).
rovider performance valuation. Performance indicators are
used for various decisions about providers, including the
allocation of pay-for-performance incentives, designation
of preferred provider status, and assignment of letter
grades and star rating categories. If a decision is to be
based on multiple indicators instead of a single indicator,
a method of translating several variables into a single
decision is needed. Composite measures serve this func-
tion by assigning providers to 1 position on a scale of
better-to-worse performance.
. Challenges Associated With
omposite Performance Measures
omposite performance measures have many practical advan-
ges, but numerous challenges are also associated with their
plementation. Individual performance measures reflect spe-
fic aspects of a provider’s quality of care, but this detailed
formation can be lost within a single summary measure. For
ample, a provider with an intermediate overall composite
ore rating relative to his or her peers may have had an
termediate performance on all of the measures or excellent
rformance on a select few and below-average performance on
hers. Distinguishing between these 2 scenarios requires knowl-
ge of the provider’s performance on each of the component
easures. Likewise, as aggregate scores, composite measures
ay not provide clinicians or policymakers with clear actionable
formation from which to target or prioritize specific quality-
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April 20, 2010:1755–66 ACCF/AHA Composite Measuresprovement efforts. The latter may be apparent only by
amining individual performance measures.
Understandably, composite performance measures can also
perceived as “black boxes” if the measures and methods
ed in their creation are not transparent and easily under-
ood. Thus, the inputs and rules used in the creation of
mposite performance measures should be clearly stated.
ven so, their impact on the actual behavior of a composite
ore may be difficult to anticipate. For instance, Example A
a composite score calculated by assigning equal weight to
ch of 3 components (structure, outcomes, and reputation).
lthough each component is weighted equally mathemati-
lly, the composite score is largely determined by just 1 of
e 3 components because the variances or spread of scores
r the individual measures are different.
In addition, the weighting of items may not always reflect
e unique interests, values, and preferences of all intended
ers. Outcomes and resource utilization might be 2 domains
a “value” composite. But patients and payers may place
fferent relative weights on these 2 performance domains (6).
rthermore, as aggregate scores, composite measures may
t provide clinicians or policymakers with clear actionable
formation with which to target or prioritize specific quality-
provement efforts. The latter may be apparent only by
amining individual performance measures.
. Development of Composite
erformance Measures
he validity and usefulness of a composite performance measure
e dependent on the quality of the individual performance
easures they are based on, as well as the robustness of the
derlying methodology used to combine these elements. The
merican College of Cardiology Foundation/American Heart
ssociation have previously outlined important criteria for
lection and creation of individual performance measures (2).
he National Quality Forum has developed a framework to
aluate the validity and utility of composite measures (7).
reation of a composite performance measure involves (1)
fining the purpose and theoretical framework for the compos-
performance measure (2), selecting individual component
easures to be considered for inclusion in the composite
rformance measure, and (3) establishing rules for how these
dividual measures will be combined and weighted. In addition,
e validity and operating characteristics of the composite
rformance measure must be carefully assessed (8).
. Defining the Purpose and
onceptual Framework of
omposite Performance Measures
he intended use of the composite performance measure
ould be clearly stated because it is the basis for selecting
d combining indicators into a meaningful summary mea-
re. Concepts such as quality of care are complex and may
compass a diverse array of possible meanings (1), depend-
g on whether the consumer is a patient, provider, payer, or
licymaker. Thus, when composite performance measures sie being developed, it is important to state clearly which
mains of quality are to be summarized. Furthermore, the
terpretation and rationale for analyzing and reporting the
osen indicators should be delineated. The potential adverse
nsequences of inclusion (or exclusion) of given factors in a
mposite performance measure should also be considered.
r example, to improve their scores, providers may focus
eir quality-improvement efforts on process measures that
e included in a composite measure while ignoring care
ocesses that are not included or not weighted heavily.
. Criteria for Selecting and Evaluating
omponent Performance Measures
pes of measures. Performance measures are traditionally
ouped into the categories of outcome, structure, and process
). Structural measures describe components or characteristics
the care delivery system thought to have an influence on
althcare delivery or health-related outcomes (e.g., physical
cilities, staff qualifications, case volume, or use of electronic
alth records). Process-of-care measures reflect what is actually
ne for a patient in terms of diagnosis, treatment, and other
pport services. Outcomes typically refer to clinical events such
mortality, morbidity, and quality of life. Beyond the triad of
ructure, process, and outcomes, metrics have been developed
measure patient satisfaction, appropriateness, and resources or
sts associated with healthcare delivery.
Tradeoff between importance and feasibility. When choos-
g among indicators, there may be a tradeoff between what
ers would like to know about a provider and what can be
easured reliably. Outcomes including mortality are often
garded as the gold standard in terms of relevance, but
tcomes require risk adjustment and can be difficult to
timate, given the low frequency of adverse events in many
tuations (2,9). Structural measures such as case volume do
t require risk adjustment and may be measured reliably, but
ese measures constitute indirect rather than direct indicators
quality. In other words, such measures are only interesting
the extent that they are surrogates for other events. Process
easurement is feasible but requires careful consideration of
tients with contraindications (2). Although statistical power
d precision are potentially enhanced by incorporating
ocess measures into assessments of providers, small sample
zes and ceiling effects (performance near 100%) are chal-
nges for some process measures (10). To date, empirical
udies have found only a modest association between nation-
ly reported cardiovascular process measures and outcomes,
cluding risk-adjusted mortality (11–13). Thus, a composite
easure that has high accuracy for measuring adherence to
idence-based care practices may have limited accuracy for
edicting an individual provider’s outcomes.
Reliability. An important criterion for evaluating an indi-
dual indicator is the extent to which differences in the
dicator between providers are explained by “true differ-
ces” (i.e., signal) versus “chance variation” (i.e., noise).
easures with a relatively high proportion of signal variance
e said to be reliable and are useful because of their high
wer for discriminating among providers. In addition, largegnal variation indicates a potential gap in quality and hence
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ACCF/AHA Composite Measures April 20, 2010:1755–66opportunity for improvement. Although highly variable
easures are desirable from the standpoint of detecting
atistically meaningful differences, the chosen end points
ust also be valid, collected reliably, and relevant to the
tended users of the composite measure.
Considerations for process measure selection. Two consider-
ions for process measure selection and evaluation are benefit
d reliability. Ideally, the evidence for these should come from
th clinical trials and observational studies (real-world set-
gs), thus linking better performance on the measure with
tter patient outcomes. As mentioned previously, processes that
e known to be effective from clinical trials and observational
udies do not always exhibit a strong association with outcomes
hen measured at the provider level. Many of these evidence-
sed performance measures and their standardized definitions
ve previously been evaluated and endorsed by specialty
cieties, accrediting organizations, and federal agencies (2).
clusion of endorsed measures is useful for ensuring a high
vel of evidence and promoting acceptance by stakeholders.
Internal consistency of indicators. When selecting indicators,
ms are frequently included or excluded on the basis of the
tent to which the items correlate with each other. Generally,
gh internal consistency between indicators is regarded as
idence that they reflect a single underlying concept or domain
4). Indicators that correlate poorly with others may be ques-
ned on the grounds that they appear to measure a different
pect or dimension. Although internal consistency is an impor-
nt concept for some methods that have been developed in the
lds of psychometrics and educational testing, the criterion of
ternal consistency has less relevance if the goal of the com-
site is to combine multiple distinct dimensions of quality as
posed to a single dimension. For example, timely reperfusion
d use of secondary prevention discharge medications are both
sential components of high-quality care for myocardial infarc-
n (MI). In empirical studies, a weak or absent association
tween performance on these 2 domains would imply low
ternal consistency, yet both would still be needed for a
mplete assessment of a hospital’s performance on MI care
ocesses. When such dissimilar elements are grouped together
to a composite, the ability to evaluate such composites based
standard psychometric criteria is limited.
. Combining Items Into a
omposite Performance Measure
umerous methods have been used to combine individual
easures or domains into composite scores, including linear
mbinations, latent trait modeling, opportunity scoring, and
e creation of patient-level composite end points such as the
l-or-none composite. These methods and related issues are
scussed below.
.1. Linear Combinations
inear combinations are weighted sums of the form w1Y1 
2Y2  . . .  wnYn, where Yi denotes the value of the i-th
dicator, n denotes the number of indicators, and wi is the
eight assigned to the i-th indicator. If the weight assigned to
ch indicator is the same (wi  1/n), then the items are
eighted equally and the sum reduces to a simple average. tivlthough linear combinations have the advantage of simplic-
and transparency, the choice of weights is not straightfor-
ard. For example, when 3 individual scores are weighted
ually within a linear combination, such a system is intuitive
t does not account for potential differences in the validity,
liability, and importance of the different individual mea-
res. For example, a score of 70% could be achieved by
eraging 2 equally weighted scores of 70% or 1 score of
% and 1 score of 90%. These may have far different
plications for both consumers and providers.
Additionally, equal weighting may be undesirable if there
a considerable imbalance in the numbers of measures from
fferent domains. For example, if 5 individual process
easures are available for quality assessment of a disease but
ly 1 outcome is obtainable, then equal weighting of each
dicator may result in a composite that is strongly reflective
care process rather than outcome performance. Even when
ual weighting of measures is the composite methodology,
e result of its application in real-world data may have
expected results (10). Example B is a composite measure
ed by CMS. Although each individual performance mea-
re is assigned equal weight mathematically, the overall
mposite is largely driven by the process measures.
Weights for a linear combination may sometimes come
om other sources such as expert panels, literature, sample
rveys, or discussions with stakeholders. In the STS com-
site performance measure (Example C), an expert panel of
rgeons weighted individual items, relying on a review of
e literature and a sample survey of the STS membership. In
e absence of strong empirical evidence on which to base
fferential weighting, the developers of the measure
eighted the 4 performance domains equally. However,
bsequent evaluation of the score demonstrated that the
lative impact of the 4 domains on the overall composite
ore was deemed to have face validity by the clinical
perts.
Regardless of how weights are determined, it is important
at they reflect the values and preferences of those using the
easure. Healthcare quality measures may have a variety of
er categories (e.g., patients, physicians, managed care
ganizations, employers). Because different stakeholders
ve different priorities, it is possible that more than 1 set of
eights (e.g., multiple composites) will be needed to meet the
eds of all potential users.
.2. Regression-Based Composite Measures
a certain outcome is regarded as a gold standard, the
eighting of individual items may be determined empirically
optimizing the predictability of the gold standard end
int. For example, acute MI performance measures might be
eighted with the goal of predicting hospital-specific mortal-
rates. An appropriate statistical framework for this pur-
se is empirical Bayesian regression modeling (15). The
eight assigned to each item is directly related to its
liability and the strength of its association with the gold
andard end point. Although regression-based weighting
ay be appropriate for predicting specific end points of
terest, such weighting may not be optimal for other objec-
es, such as motivating healthcare professionals to adhere to
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April 20, 2010:1755–66 ACCF/AHA Composite Measuresecific treatment guidelines. Specifically, evidence-based
ocess measures would not contribute to such a composite
less there was evidence of a strong empirical association
tween provider-level process performance and the criterion
interest.
.3. Latent Trait Composite Measures
multiple indicators are assumed to measure 1 dimension of
re, the method of combining these indicators may be opti-
ized by predicting 1 latent variable that reflects this dimension.
his concept is the foundation of several psychometric methods,
cluding versions of factor analysis, item-response modeling,
d principal components analysis (16–19). To estimate a single
tent trait, it is necessary that the various trait indicators pertain
a single dimension only rather than multiple distinct aspects of
re. This distinction can be made from subject matter consid-
ations and empirical testing. The assumption of unidimension-
ity may not be appropriate for a comprehensive measure that
ans multiple domains of quality. For instance, a latent trait
mposite measure of acute MI might suppose that quality of
re is consistent within a given hospital, although patients with
ute MI receive care from multiple teams. It is quite possible
at although the hospital’s performance in acute process (e.g.,
ovision of rapid reperfusion) may be excellent, its performance
provision of secondary prevention measures at hospital
scharge may be poor, thus violating the single latent trait
ncept. However, it may be possible to identify clusters of
rrelated items so that the assumption of unidimensionality
plies to all items in a single cluster. In this case, latent trait
odeling may be used to combine items within clusters but not
ross clusters. The problem of how to weight fundamentally
fferent dimensions of quality is beyond the scope of most
ychometric methods.
Because psychometric methods may not be suitable in
tuations for which the unidimensionality assumption is
tenable, in 1987 Feinstein introduced the “clinimetric”
proach (20). This concept attempts to more specifically
rve the aim of clinicians, “which is to choose and empha-
ze suitably the most important attributes to be included in
e index, using multiple items which are not expected to be
mogeneous because they indicate different aspects of a
mplex clinical phenomenon” (p 234) (21). The selection
d weighting of items is based on deliberate judgment and is
nsidered successful if the behavior of the composite score
consistent with the developer’s intentions.
.4. Opportunity Scoring
n opportunity-based score is an alternative to simple averaging
ten used for aggregating individual process measures. Oppor-
nity scoring counts the number of times a given care process
as actually performed (numerator), divided by the number of
ances a provider had to give this care correctly (denominator).
nlike simple averaging, each item is implicitly weighted in
oportion to the percentage of eligible patients, which may vary
om provider to provider. This method has the advantage of
creasing the number of observations per unit of measurement,
nsequently potentially increasing the stability of a composite
timate, particularly when the sample size for individual mea-
res is not adequate. But these advantages can also be disad- Stntages because opportunity-based composite scores will inev-
bly be most influenced by the most common care processes,
gardless of whether or not they are the most important methods.
.5. All-or-None Scoring of Process Measures
all-or-none scoring (also known as defect-free scoring), the
tient is the unit of analysis. Only those patients who receive all
dicated processes of care are counted as successes. Perfor-
ance is defined by the proportion of patients receiving all of the
ecified care processes for which they were eligible. No credit
given for patients who receive some but not all required items.
his method has been advocated on the grounds that it promotes
high standard of excellence (22). A counterargument is that
chotomizing outcomes as all or none wastes valuable infor-
ation (23) and may weight common but less important pro-
sses more heavily than infrequent but important processes.
ll-or-none scoring gives the same credit for achieving none of
measures as it does for achieving 4 of 5 measures.
.6. Any-or-None Scoring of
utcome Measures
ny-or-none scoring is an analogous method for combining
tcomes rather than processes. In this method, a patient is
unted as failing if he or she experiences at least 1 adverse
tcome from a list of 2 or more adverse outcomes. Such end
ints are commonly used in randomized clinical trials of
rdiovascular therapies when the analysis of mortality alone
ould require an extremely large sample size. As noted by
any authors, such composite outcomes may be misleading if
e component items occur with unequal frequency or vary in
eir importance (24–26). Any-or-none composite outcomes
e particularly problematic when rare but important out-
mes are mixed with common but relatively unimportant
tcomes, because the composite is likely to be dominated by
e outcome that occurs most frequently.
.7. Incommensurable Measurement Scales
rformance measures are evaluated on various different scales
d therefore must be transformed into a common scale before
ing combined. Some methods of rescaling include 1) dividing
ch measure by its standard deviation, 2) dividing each measure
its range, 3) assigning scores based on the provider’s
rcentile ranking, and 4) assigning a specified number of points
the provider’s score exceeds a certain threshold (e.g., above
e mean or median) (8). Although different methods of rescal-
g may produce different results, these inconsistencies are often
btle, particularly when compared with the effect of no stan-
rdization at all (18,27). Example C illustrates rescaling used in
e creation of the STS coronary artery bypass graft composite
ore methodology.
. Statistical Models for Estimating
omposite Performance Measures
rformance measures are susceptible to chance fluctuations,
en when performance remains constant. Because these
ctuations are partly random, there is always some degree of
certainty about a provider’s true underlying performance.
atistical methods and models have been developed to
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ACCF/AHA Composite Measures April 20, 2010:1755–66count for this source of uncertainty when estimating individual
composite measures used to compare provider performance.
Random effects modeling (also known as hierarchical mod-
ing) is a commonly used statistical model for estimating
ovider performance. Unlike simple percentages and averages,
random effects model uses data from all analyzable providers
estimate performance measures for 1 provider. This “borrow-
g of information” across providers produces estimates with
od statistical properties, including smaller standard errors than
nventional estimates. The random effects model–based esti-
ate can be viewed as a weighted average of a provider’s actual
ore for a singular measure and the overall average score for all
oviders in the analysis database. The model weights an
dividual provider’s own data more heavily when the denom-
ator is large enough to be reliable and weights the overall
erage score more heavily when the provider’s denominator is
o small to support a reliable performance estimate.
Random effects models are commonly used to analyze a
ngle outcome, such as mortality. But extensions to multiple
tcomes are straightforward and have been used to measure
e quality of adult cardiac surgery (15,27). When multiple
tcomes are analyzed simultaneously, information is not
ly borrowed across providers but across outcomes. For
ample, information on a provider’s mortality rate may help
prove estimation of performance with respect to other
nfatal outcomes (e.g., stroke rate, infection rate) that are
atistically associated with mortality.
Although model-based estimates are useful for estimating
pulation parameters and predicting future outcomes, they
e less transparent than simple unadjusted percentages and
w averages. Because random effects estimates are a com-
nation of an individual provider’s own data and data
rrowed from other providers, the resulting estimate does
t provide a simple summary of what actually occurred in
e sample of patients treated by a single provider. Moreover,
a result of the “shrinkage” property of random effects
timates (i.e., moving a provider’s measured performance
oser to the overall population mean), for providers with a
ry small number of patients, the estimates tend to be close
the overall provider average, regardless of actual results.
lthough model-based approaches provide more reliable
timates, the construct validity of this approach may be more
oblematic for some stakeholders because a provider’s
timate depends partly on the performance of other providers.
Although hierarchical model–based estimates are often
eferred on the grounds that they are less variable than
nventional estimates, they are still prone to large errors in
e presence of small sample sizes, so these estimates should
accompanied by a measure of precision. In some contexts,
ch as public reporting, interval estimates, which consist of
range of plausible estimates, are more appropriate.
0. Reporting Issues Associated With
omposite Performance Measures
0.1. Rescaling and Categorization
hen a composite performance measure is formed by aver-
ing items with different measurement scales (e.g., survival vates and staffing ratios), the scale of the resulting average
mposite will not be inherently meaningful or interpretable.
such cases, rescaling the composite to lie between 1 and
0 (or another familiar range) may enhance the perceived
terpretability of the composite. When rescaling a composite
easure, consideration should be given to the clinical and
atistical significance of the observed variation in the com-
nent items. The scale should not create the false impression
large differences between providers if in fact these differ-
ces are negligible. In some cases, converting the composite
rformance measure to a small number of categories (e.g., 1
3 “stars”) may enhance communication and graphic pre-
ntation. As with rescaling, in categorization there is a risk
exaggerating true differences between providers if the
tual differences are statistically or clinically insignificant.
0.2. Measures of Precision
eporting of composite measures should be accompanied by
estimate of the uncertainty caused by random statistical
ctuations. Ignoring this source of uncertainty may lead
ers to overestimate the reliability of the data and to draw
lse conclusions about performance. When comparing pro-
ders with each other or with a benchmark, reports should
dicate whether the observed differences are within the
unds of normal sampling variation.
0.3. Reporting of Component Items
addition to reporting the overall composite performance
easure, the composite score should be capable of decon-
ruction. A composite score should be broken down into
ores for each component domain or individual measure.
oviding deconstructed detailed data are critical for 2 main
asons: 1) detailed data allow providers to focus their quality
provement efforts and 2) because the weighting of indica-
rs may not optimally reflect an individual user’s prefer-
ces, detailed data allow interested users to reconstruct and
just the composite measure based on their own values or
rpose. It is also suggested that composite performance
easures include some indication of the number of cases in
e numerator and denominator if relevant.
0.4. Dealing With Missing Data
he performance of a composite measure applied to real-
orld settings can be compromised by missing data. First and
remost, developers should have a defensible strategy for
anaging missing data. Case-wise deletion of records with
issing data can be problematic because information is
asted when some but not all of the required information is
issing. This may cause bias if data are not randomly
issing. Imputation of missing data is generally preferred to
se-wise deletion of records but may cause bias if the
puting method is not statistically rigorous. When feasible,
chniques such as resampling and multiple imputation
ould be used. These techniques appropriately account for
e uncertainty associated with missing data and produce
lid point estimates and confidence intervals.
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April 20, 2010:1755–66 ACCF/AHA Composite Measures1. Evaluation of Composite
erformance Measures
lthough the selection of methodology and weights for a
mposite performance measure may be subjective, develop-
s of composite measures must fully explore the implications
the chosen approach and verify that the resulting compos-
measure behaves in a manner that is intuitively acceptable
d consistent with the intended purpose and interpretation.
1.1. Exploring Behavior of Composite
erformance Measures
ne way to evaluate the behavior of a composite performance
easure is to determine the amount of improvement needed
1 variable to offset worsening in another variable. A second
ethod of elucidating the implications of weights involves
lculating the correlation coefficient between each individual
m and the overall composite. A very low correlation
tween 1 item and the composite suggest that the weight
signed to the item may be too low to substantially influence
e overall composite. An exceptionally strong correlation
tween 1 item and a composite suggests that much of the
riation in the composite can be explained by a single item.
1.2. Sensitivity Analysis
ften more than 1 method of creating a composite measure is
asonable and consistent with the intended purpose of the
mposite measure. In such cases, developers should explore
variety of these methods and document whether conclusions
out provider performance differ substantially depending on
e choice of method (6,8,10,28). If different versions of the
mposite measure are based on different weights and highly
rrelated, the choice between alternative weighting methods
s relatively little practical importance. As a result, this issue
n be safely ignored. On the other hand, if different weights
oduce widely divergent results, then this uncertainty should
considered by composite measure users, and conclusions
out performance may be tempered.
2. Assessing the Validity of Composite
erformance Measures
he validity of a composite performance measure depends on
e purpose for which it is applied. For example, a composite
rformance measure that is composed of several process
easures may have excellent validity for summarizing a hospi-
l’s performance on process measures but poor validity for
edicting a hospital’s outcomes. Documenting the intended
rpose and interpretation of the composite score will help
sure that the composite score is evaluated for its intended purpose.
2.1. Construct Validity
composite performance measure is said to have construct
lidity if it truly measures what it purports to measure. An
portant aspect of construct validity is content validity,
hich is defined as the presence of all important content
pects in the available indicators. If crucial items are
issing, then the concept may need to be reformulated to
flect the available indicators.2.2. Face Validity
composite performance measure should also be tested for
ce validity, which is acceptance by stakeholders that the
easure is useful and valid. Face validity is partly based on
reement that a composite measure has good construct
lidity. Acceptance of a composite performance measure is
so enhanced by use of methods and a reporting format that
e easily understood.
2.3. Criterion Validity
riterion validity implies that the composite score correlates
ghly with an end point that may be regarded as a gold-
andard method of measuring the concept of interest. If the
al of the composite performance measure is to identify
spitals with excellent outcomes, then criterion validity
ight be assessed by comparing predictions based on the
mposite performance measure with observed outcomes,
cluding mortality. Yet criterion validity is difficult to
tablish for multidimensional composite scores, primarily
cause the concept being measured is ill-defined and thus
cks a criterion standard.
2.4. Precision/Reliability
measure is said to be precise or reliable if the amount of
riation in the composite that is caused by random statistical
ctuations is small, relative to variation caused by true
fferences between units. The acceptable level of precision
pends on the context in which the measure is used.
easures dominated by chance variation may be harmful in
at they can result in unfair conclusions about providers and
islead consumers.
3. Recommendations
he writing committee considers the following as necessary
the development and implementation of any composite
rformance measure used for public reporting or other forms
accountability. When used solely for the purposes of
ternal quality improvement, however, it may be reasonable
use criteria that are somewhat less strict.
The intended audience and purpose of the composite perfor-
mance measure should be explicitly stated. This will provide
the basis for selection of individual indicators and provide
direction for methods of aggregation and weighting.
Decisions about what to measure should be based on the
clinical importance associated with important patient out-
comes and the reliability of individual performance mea-
sures. Assumptions underlying the choice of measures
should be documented. Ideally, component measures
should be tested before they are included in a composite
performance measure.
Each individual component should be precisely defined to
ensure consistent application in different settings.
The description of the methods used for weighting and
combining individual measures into a composite perfor-
mance measure should be transparent. The strengths and
limitations of the selected method should be considered
and discussed.
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ACCF/AHA Composite Measures April 20, 2010:1755–66Developers should explore a variety of alternative meth-
ods for combining measures and should document whether
conclusions about provider performance differ with use of
alternative methods.
Empirical testing should be performed to assess the
properties of a composite measure score and to understand
what is being measured. The considerations of validity and
reliability typically are viewed as essential elements for
determining the quality of any test.
Reporting of composite performance measures should be
accompanied by detailed reporting of individual domains
and components.
Reporting of composite performance measures should
include a measure of the degree of uncertainty surrounding
composite estimates for providers.
Composite performance measures based on scientific ev-
idence must be reevaluated as that evidence changes.
Additionally, the operating characteristics of a given
composite performance measure should be periodically
reevaluated for reliability and validity to ensure that they
have not changed over time.
Example A. US News & World Report Index of Hospital
uality for Heart and Heart Surgery. The US News & World
eport Index of Hospital Quality is the basis for evaluating
spitals in the magazine’s annual “Best Hospitals” report (29).
he Index of Hospital Quality for heart and heart surgery is a
ear combination of 3 equally weighted components: reputa-
n, risk-adjusted mortality, and structure. Although the 3
mponents are weighted equally, the recognition scores appear
be the most variable (ranging from 0 to 65 in 2008). Figure 1ows the strong linear correlation between a hospital’s reputa-
n score and its overall Index of Hospital Quality score,
ggesting that the reputation component is highly influential in
termining the relative rank ordering of these 10 hospitals
anel A). In comparison, the Mortality Index (Panel B) appears
have much less influence.
Example B. The Centers for Medicaid and Medicare
rvices Hospital Quality Incentive Demonstration. In the
enters for Medicaid and Medicare Services Hospital Quality
centive Demonstration Project, a composite measure was used
r assigning financial bonuses and penalties to hospitals in a
lot pay-for-performance project (4). For coronary artery by-
ss graft surgery, the composite quality score (CQS) was based
an equally weighted combination of 7 measures (4 process
easures and 3 outcome measures). Thus, at first glance it might
thought that the overall composite would assign 4/7 of the
eight to processes and 3/7 of the weight to outcomes. Indeed,
is is true, based on a mathematical description of the aggre-
tion method. But despite this equal mathematical weighting,
e actual publicly reported data suggest that the CQS was more
avily influenced by process measures than would have been
pected by the apparent 4:3 weighting. This point is illustrated
Figure 2, which depicts data from the top 50% of hospitals in
ar 1 of the project. As seen in Panel A, there is a near perfect
creasing relationship between a given hospital’s performance
process measures and a given hospital’s decile ranking (based
overall CQS). In contrast, as seen in Panel B, there is almost
relationship between a given hospital’s performance on
tcome measures and a given hospital’s ranking. The explana-
n is that compared with the process measures, the outcomes
Figure 1. Index of hospital quality scores for
the top 10 ranked heart and heart surgery
hospitals in 2008 relative to their reputation
and mortality scores.
Figure 2. Data from top 50% of hospitals in
year 1 of the Centers for Medicaid and Medi-
care Services Hospital Quality Incentive
Demonstration reporting process measures
versus outcome measures.
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April 20, 2010:1755–66 ACCF/AHA Composite Measureseasures have a relatively small standard deviation. When items
ith a small standard deviation are averaged with items with a
rge deviation, items with the large standard deviation tend to
minate the average.
Example C. Society of Thoracic Surgeons Composite
easurement Methodology for Adult Cardiac Surgery.
he STS Composite Measurement Methodology, published
2005, is a linear combination of scores from 4 separate
mains: risk-adjusted mortality, risk-adjusted morbidity, an
traoperative surgical process measure (use of the internal
ammary artery [IMA]), and several adjuvant perioperative
edications (5). To create the composite, the 4 subcompo-
nt domain scores were first standardized by dividing their
spective standard deviations and then averaged together
ith equal weighting of each component score.
The consequences of this standardization and weighting
proach were explored analytically and empirically. From an
alytic perspective, assigning equal weight to the standardized
main scores was shown to be mathematically equivalent to
signing unequal weights to the original domain scores, which
ere not standardized. The “weight” assigned to a given score
as proportional to the reciprocal of its standard deviation. Thus,
is approach reduced the relative weighting of items with larger
andard deviations and increased the relative weighting of items
ith smaller standard deviations.
Pilot studies showed that the risk-adjusted mortality domain
ore had the smallest standard deviation, followed by risk-
justed morbidity, IMA, and medications. After dividing each
main score by its standard deviation, it was shown that a
percentage point improvement in a provider’s risk-adjusted
rvival rate would increase the overall composite score by the
me amount as an 8.4-percentage point improvement in the*Significant (greater than $10 000) relationship.orbidity rate, an 11.6-percentage point improvement in IMA
age, or a 28.6-percentage point improvement in medication
age. Additional empirical studies showed that no single item
minated the composite and that all 4 domains contributed
bstantial statistical variation. This behavior was deemed rea-
nable by the STS expert panel that developed the composite.
he approach was endorsed by the STS Executive Committee
fore its public use.
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